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Abstract: Choroideremia is a complex and rare disease that is frequently misdiagnosed due 
to its similar appearance to classic retinitis pigmentosa. Recent advances in genetic testing 
have identified specific genetic mutations in many retinal dystrophies, and the identifica-
tion of the mutation of the CHM gene on the X chromosome 25 years ago has paved the 
way for gene replacement therapy with the first human trials now underway. This article 
reviews the epidemiological and pathological features of choroideremia and new prospects 
in imaging to monitor disease progression, as well as potential treatment approaches for 
choroideremia.
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Introduction
Choroideremia is an X-linked, recessive disease of the retina resulting in progressive 
degeneration of the retina, the retinal pigment epithelium (RPE), and the choroid. The 
prevalence of choroideremia is estimated to be approximately 1:50,000 in people of 
European descent.1
The disease is characterized by the clinical appearance of atrophy of the choroid 
resulting in a characteristic pale color of the fundus, originating from the translucence 
of the white sclera (Figure 1). In males, the condition gradually advances and starts 
with night blindness and eventually results in progressive loss of peripheral vision 
and total blindness in the late stages, although some extreme peripheral field detec-
tion may remain.2 However, disease progression is relatively slow and the fovea is 
generally only affected in the end stages of the disease. Therefore, patients may retain 
good central visual function as late as 50–70 years old.3,4
Although X-linked diseases preferentially occur in men (as they have only one 
X chromosome) choroideremia may also present in female carriers. Carrier females 
may show characteristic pigmentary changes of the fundus with patchy chorioretinal 
degeneration. This is due to the process of lyonization in which one copy of the 
X chromosome is silenced5 and therefore cells carrying the mutation are intermixed 
with cells expressing the normal X chromosome resulting in a mosaic pattern of 
the disease. Therefore, most female carriers are asymptomatic and maintain normal 
visual acuity. The characteristic fundus appearance and a family history consistent 
with X-linked disease are sufficient for the diagnosis of choroideremia. Other reti-
nal dystrophies with similar fundus appearance can usually be ruled out by family 
history or laboratory testing. These include autosomal recessive gyrate atrophy 
which can usually be ruled out by family history and testing for hyperornithinemia, 
Oliver–McFarlane syndrome, a PNPLA6-related disorder and dominantly negative 
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Figure 1 Fundus color photographs of the right and left eye of a patient with advanced choroideremia.
Note: There is a residual island of healthy tissue in the central macula and fovea (white arrows).
mutations in RPE65 or bifocal chorioretinal atrophy, and 
an autosomal dominant disease with a gene mutation on 
chromosome 6.6–8
There are several reports on the histological changes in 
choroideremia – this is critically important for designing 
treatments, because it is essential to know which retinal cells 
are affected by the CHM gene deficiency and therefore need 
to be targeted by gene therapy vectors. In postmortem his-
tological sections, independent degeneration of choriocap-
illaris, RPE, and neurosensory retina have been described. 
Furthermore, areas of relatively well-preserved retinal 
architecture were found adjacent to areas of severe degen-
eration, corresponding to the clinical fundus appearance.9,10 
Photoreceptor degeneration was less pronounced above 
preserved RPE, but occasionally photoreceptor loss was 
seen in areas with preserved RPE.11 Within the affected 
areas, the retina was thinned due to thinning of outer seg-
ments of the photoreceptors and loss of nuclei within the 
outer nuclear layer. Subsequently, loss of nuclei within 
the inner nuclear layer was found as well.11 In addition, 
there was profound rarefication of most vasculature and 
melanocytes within the choroid. There is some evidence 
that inflammation occurs within the retina in patients with 
choroideremia: a recent report has provided evidence of a 
mild T-lymphocytic infiltration within the choroid.11 Fur-
thermore, pigment filled macrophages have been identified 
in the subretinal space associated with rosette formation of 
the retina.12 Whereas inflammation is not likely to play an 
active part in the pathogenesis of choroideremia, there seems 
to be a reactive inflammatory response in the areas of active 
disease as photoreceptor debris usually is phagocytized and 
removed by macrophages.13
Retinal imaging in choroideremia 
and implications for gene 
replacement therapy
In the last decade, advances in retinal imaging have led to an 
improved understanding of morphological changes occurring 
during the disease course of choroideremia. Optical coher-
ence tomography (OCT) can be used to diagnose macular 
changes associated with choroideremia such as choroidal 
neovascularization,14 cystoid macular edema,15 epiretinal 
membrane formation,16 outer retinal tubulations,17 macular 
hole formation,18 and macular hole complicated by retinal 
detachment.19 Fundus autofluorescence shows a characteristic 
speckled pattern of low- and high-density fundus autofluores-
cence (Figure 2).20 Increased lipofuscin accumulation origi-
nating from digestion of degenerating rods by RPE cells is 
thought to cause increased autofluorescence in choroideremia, 
whereas low density fluorescence reflects loss of the RPE 
layer whilst the choroid is still intact. This is corroborated 
by functional tests, showing an association of multifocal 
electroretinogram (mfERG) deterioration with major fundus 
autofluorescence changes.20,21 Despite high resolution OCT 
and genetic characterization of choroideremia, the sequence 
of morphological changes leading to vision loss remains 
unknown. There are several theories on which retinal layers 
are primarily affected by choroideremia. Whereas some reports 
show that the RPE is the first layer to degenerate, followed by 
loss of photoreceptors,22 others claim that the photoreceptor 
layer,23 in particular the rods,24 is primarily affected, followed 
by degeneration of the RPE and the choriocapillaris. The lat-
ter hypothesis is not however supported by the observations 
from patients with dominant RPE65 mutations who have a 
very similar choroidal atrophy appearance to CHM. Since the 
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Figure 2 Multimodal imaging of a patient with choroideremia.
Notes: (A) Fundus AF showing an island of hyperfluorescent intact retina (delineated by white arrows). (B) iR image with corresponding OCT scan line (the green line 
represents the OCT scan direction) and (C) OCT images of the same patient. in OCT, the marked atrophy of the retinal pigment epithelium with homogenously increased 
reflectivity in OCT corresponds well with the borders seen in AF. There is a marked thinning of the outer nuclear layers and the choroidea is virtually absent, both hallmarks 
of choroideremia.
Abbreviations: AF, autofluorescence; OCT, optical coherence tomography; IR, infrared.
RPE65 gene is known to be expressed only in the RPE and 
being dominantly negative, we assume it causes RPE cell 
death; this phenotype provides an alternative pathway for the 
choroidal atrophy being RPE-driven in both diseases. Con-
versely, if CHM were a disease primarily of rod photoreceptor 
loss, then we might expect it to appear similar to the other 
forms of rod-cone dystrophy (retinitis pigmentosa).
Cone loss at the fovea and smaller atrophic-appearing 
cones at the edge of degeneration have also been found 
using adaptive optics scanning laser ophthalmoscopy.25 
Functional tests such as mfERG and microperimetry are 
already employed to monitor therapeutic responses after gene 
replacement therapy. Future developments in imaging of reti-
nal dystrophies should aim at identifying risk factors and reli-
able markers for disease progression. Here, several imaging 
modalities such as OCT angiography or fluorescence lifetime 
imaging ophthalmoscopy may provide disease specific infor-
mation. In a recent report using en face OCT angiography, 
it has been shown that choriocapillaris nonperfusion was 
more pronounced than the retinal nonperfusion in patients 
with choroideremia. The observed choriocapillaris nonper-
fusion is thought to follow the RPE loss and may therefore 
possibly represent a marker for disease progression and/
or response to treatment.26 Fluorescence lifetime imaging 
ophthalmoscopy is a novel imaging modality able to quantify 
fluorescence lifetimes in the retina.27,28 In contrast to fundus 
autofluorescence, fluorescence lifetimes are influenced by 
metabolic changes within the retina. Therefore, this imaging 
modality may be valuable to identify areas at risk for disease 
progression in retinal dystrophies and may be a valuable tool 
to assess therapeutic responses. The exact sequel of structural 
changes occurring within the retina has received increasing 
interest in the last years in light of emerging therapies for 
retinal diseases.
Genetics of choroideremia
Choroideremia is caused by mutations in the CHM gene, 
located on the long arm of the X chromosome, encoding 
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the 95 kDa protein Rab escort protein 1 (REP1). The REP1 
gene is ubiquitously expressed and acts as an escort protein 
of native regulators of intracellular trafficking. The deletions 
in the CHM gene causing choroideremia were first described 
in 1990.29,30 Mutations in the CHM gene have been identi-
fied in European,31–35 Canadian,36 American,37 Japanese,38 
and Chinese families.39 These mutations cause truncation 
or absence of REP1, which plays an essential role in the 
intracellular vesicular transport. REP1 is involved in lipid 
modification of Rab proteins by binding newly synthesized, 
unprenylated Rabs and presenting them to a catalytic Rab 
geranylgeranyltransferase or farnesyltransferase subunit for 
the geranylgeranyl transfer reaction.40 Furthermore, REP1 
facilitates transport of prenylated Rabs to their specific desti-
nation membrane by binding to the hydrophobic prenylation 
motifs at their C termini.41 Rab proteins are present in all cells 
and so far more than 50 Rab proteins have been identified.42 
Within the eye, many processes such as transport of proteins 
within the photoreceptors or regulation of phagocytosis and 
degradation of disc membranes shed from the outer seg-
ments of photoreceptors by RPE are reliant on Rab protein 
function. Generally, loss of REP1 is compensated by Rab 
escort protein 2, a protein that closely resembles REP1 and 
is encoded by the X-linked retrogene CHML (choroideremia-
like), which is located on chromosome 1.43 Most newly 
synthesized Rabs bind to one of the two REP proteins and 
therefore mutations in CHM generally do not lead to sys-
temic disease. A possible explanation for the eye restricted 
phenotype is that some Rabs, such as Rab 27a which has a 
key role within the retina,44 are preferentially prenylated by 
REP1 or that REP2 prenylated Rab27a complexes may have 
a lower affinity to geranylgeranyltransferase.45 Therefore, 
the phenotype of choroideremia may be mainly caused by 
a tissue specific inability of REP2 to compensate for the 
function of REP1.
Review of recent developments in 
therapies for choroideremia
The retina is unusually accessible in the evaluation of trials 
of gene therapy. Not only can disease progression be imaged 
in nearly histological detail using high resolution OCT, but 
also there are several functional tests available to monitor 
therapeutic responses. Furthermore, modern vitreoretinal 
techniques allow for controlled and local delivery of gene 
replacement products to the affected tissue. Extensive prelimi-
nary work in mouse and dog models of retinal degeneration 
have shown that the use of adeno-associated vectors to deliver 
gene replacement therapy in the retina is safe and may result 
in stable and substantial restoration of the gene product and 
functional improvement.46 Of the many different adenoassoci-
ated virus (AAV) subtypes, AAV2 has a reasonable affinity 
for primate photoreceptors and RPE,47 but has the advantage 
over other serotypes in being well characterized in a number of 
animal models. Therefore, AAV2 has been used as the vector 
for gene replacement therapy in several gene therapy trials 
for retinal dystrophies.48–51 Because the amount of genetic 
material is limited by the packaging capacity of the vector, 
the size of gene to be replaced is of critical relevance. The 
limit for AAV vectors is estimated to be around 5 kb for single 
stranded DNA.52 With a total size of approximately 1.9 kb, 
the coding sequence of REP1 fits well within the packaging 
limit of AAV2 with spare space for other regulatory elements, 
such as the promoter and poly-A signal sequences.
Preclinical studies have shown the feasibility of REP1 
replacement therapy using AAV2 in Chmnull/+ mice. In Chmnull/+ 
mice, selective ablation of Chm in photoreceptor cells or the 
RPE results in independent degeneration of both of these 
layers resembling the clinical phenotype of choroideremia.53 
Using AAV2-REP1 delivered subretinally, a dose-dependent 
improvement of retinal function was observed in Chmnull/+ 
mice. These findings served as proof of concept for future 
clinical gene replacement therapies in humans.54
Retinal gene therapy in humans involves delivery of a 
viral vector to the photoreceptors and the RPE. In order to 
reach this tissue, a pars plana vitrectomy is necessary, fol-
lowed by a small retinotomy and subretinal injection of fluid 
containing the vector. This procedure is highly complex 
because it must be done without damaging the fovea in a 
degenerate retina. The injection, to some extent, resembles 
subretinal injection of recombinant tissue plasminogen acti-
vator for the treatment and displacement of subretinal hemor-
rhage, although in these cases the retina is already detached 
and the visual acuity is severely compromised. In CHM, 
the potential risks of subretinal gene therapy should not be 
underestimated as the delivery of the vector entails detach-
ment of the fovea which may lead to reduction of contrast 
sensitivity or even visual acuity. Furthermore, it is unknown 
whether or not the gene product or the vector might cause an 
immune reaction with potentially detrimental effects to the 
retina in some individuals.
Recently, preliminary results of a Phase I–II clinical trial 
assessing the effects of the AAV2-REP1 vector in six patients 
with choroideremia have been published.55 In this report, 
gene therapy with AAV2-REP1 was shown to be safe with 
a greater than 2- and 4-line improvement of visual acuity in 
two patients. Furthermore, it was shown that the five patients 
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who received the full dose of AAV vector had improvements 
in mean retinal sensitivity. In this study, only patients with 
advanced disease with macular involvement were included. 
Four patients had near normal best corrected visual acuity at 
baseline and detachment of the fovea, which was required for 
gene replacement delivery, was shown to be well tolerated 
in these patients. Future prospects of gene replacement 
therapy in patients with choroideremia should target patients 
at an early disease stage when the retinal architecture and 
function are still intact. This has several implications for 
the clinician. Because there is now a potential therapy for 
patients with choroideremia and other retinal dystrophies, 
counseling of patients in clinics should include information 
on current results of gene replacement trials. Furthermore, 
genetic testing and molecular diagnosis of the DNA or mes-
senger RNA causing retinal dystrophy should be used to 
support the clinical diagnosis. Even in the case of clinically 
confirmed choroideremia, genetic confirmation should be 
obtained in order to determine whether a patient is suitable 
for future gene replacement therapy trials. In addition, it is 
important to establish a database of patients with confirmed 
genetic mutations to inform patients of forthcoming gene 
replacement therapies and offer them the possibility of 
participating in future trials.
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